SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-110621
Filing Date
2020-04-17
Accepted
2020-04-17 16:05:43
Documents
12
Period of Report
2020-04-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d914239d8k.htm   iXBRL 8-K 23766
  Complete submission text file 0001193125-20-110621.txt   141967

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20200413.xsd EX-101.SCH 3067
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20200413_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20200413_pre.xml EX-101.PRE 10951
6 EXTRACTED XBRL INSTANCE DOCUMENT d914239d8k_htm.xml XML 3282
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 20799727
SIC: 2836 Biological Products, (No Diagnostic Substances)